Acadia Pharmaceuticals, Q3 2026 Earnings Call Transcript

Acadia reported third-quarter revenue of $342 million, up 22% year over year on an adjusted basis. DAYBUE sales rose 39% to a record $140 million, supported by uptake of the STIX formulation, new patients and restarts; the company raised its 2026 sales outlook and reiterated its ambition of $700 million in sales by 2028. NUPLAZID sales increased 12% to $202 million, mainly on volume growth. Its 2026 outlook was narrowed, while Acadia maintained its goal of approximately $1 billion in sales by 2028. DAYBUE received EU approval, and a new U.S. patent is expected to protect both formulations through March 2041.

In the Phase II RADIANT study, remlifanserin narrowly missed statistical significance on the primary endpoint, but showed activity at 60 mg across four measures and a safety profile similar to placebo. Acadia plans to advance the 60 mg dose in Phase III, drop the 30 mg arm and refine trial conduct and statistical methods; Phase II results for Lewy body dementia psychosis are expected in Q4 2027. ACP-211 results in major depressive disorder are expected in the second half of 2027. The company says pipeline investment will be guided by the evidence generated by each program.